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Summary
Background High-resolution estimates of HIV burden across space and time provide an important tool for tracking 
and monitoring the progress of prevention and control efforts and assist with improving the precision and efficiency 
of targeting efforts. We aimed to assess HIV incidence and HIV mortality for all second-level administrative units 
across sub-Saharan Africa.
Methods In this modelling study, we developed a framework that used the geographically specific HIV prevalence 
data collected in seroprevalence surveys and antenatal care clinics to train a model that estimates HIV incidence and 
mortality among individuals aged 15–49 years. We used a model-based geostatistical framework to estimate 
HIV prevalence at the second administrative level in 44 countries in sub-Saharan Africa for 2000–18 and sought data 
on the number of individuals on antiretroviral therapy (ART) by second-level administrative unit. We then modified 
the Estimation and Projection Package (EPP) to use these HIV prevalence and treatment estimates to estimate 
HIV incidence and mortality by second-level administrative unit.
Findings The estimates suggest substantial variation in HIV incidence and mortality rates both between and within 
countries in sub-Saharan Africa, with 15 countries having a ten-times or greater difference in estimated HIV incidence 
between the second-level administrative units with the lowest and highest estimated incidence levels. Across all 
44 countries in 2018, HIV incidence ranged from 2·8 (95% uncertainty interval 2·1–3·8) in Mauritania to 1585·9 
(1369·4–1824·8) cases per 100 000 people in Lesotho and HIV mortality ranged from 0·8 (0·7–0·9) in Mauritania 
to 676·5 (513·6–888·0) deaths per 100 000 people in Lesotho. Variation in both incidence and mortality was 
substantially greater at the subnational level than at the national level and the highest estimated rates were 
accordingly higher. Among second-level administrative units, Guijá District, Gaza Province, Mozambique, had the 
highest estimated HIV incidence (4661·7 [2544·8–8120·3]) cases per 100 000 people in 2018 and Inhassunge District, 
Zambezia Province, Mozambique, had the highest estimated HIV mortality rate (1163·0 [679·0–1866·8]) deaths per 
100 000 people. Further, the rate of reduction in HIV incidence and mortality from 2000 to 2018, as well as the ratio 
of new infections to the number of people living with HIV was highly variable. Although most second-level 
administrative units had declines in the number of new cases (3316 [81·1%] of 4087 units) and number of 
deaths (3325 [81·4%]), nearly all appeared well short of the targeted 75% reduction in new cases and deaths between 
2010 and 2020.
Interpretation Our estimates suggest that most second-level administrative units in sub-Saharan Africa are falling 
short of the targeted 75% reduction in new cases and deaths by 2020, which is further compounded by substantial 
within-country variability. These estimates will help decision makers and programme implementers expand access to 
ART and better target health resources to higher burden subnational areas.
Funding Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
As the HIV pandemic enters its fifth decade, several 
indicators have been proposed to help describe the 
burden of HIV, measure the effectiveness of public 
health efforts, and guide decision making. Among 
the most useful and commonly cited indicators are 
the HIV incidence rate, the HIV mortality rate, the 
percentage reduction in the number of incident 
HIV cases and HIV deaths, and the ratio of incident 
HIV cases to people living with HIV.1 The UN Political 
Declaration on HIV and AIDS calls for a 75% reduction 
in new HIV infections and HIV deaths from 2010 to 2020.2 
Studies have shown that geographical targeting of 
resources can improve the efficiency and effectiveness 
of interventions and strategies intended to address HIV.3,4 
To best aid resource targeting, HIV indicators need to be 
produced at a refined spatial scale. Yet, for countries in 
sub-Saharan Africa—those hardest hit by the HIV 
pandemic—collecting data on indicators of HIV incidence 
and mortality remains a challenge, particularly at 
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spatially granular levels, where weaknesses in civil 
registration and vital statistics systems are typically 
beyond the capacity or funding for HIV programmes 
alone to address. Historically, most data collection 
systems for tracking HIV have focused on measuring 
HIV prevalence, partly because HIV prevalence is 
inherently more straightforward to measure than 
HIV incidence or mortality, and partly driven by pro-
grammatic needs including daily patient management, 
ensuring sufficient drug supply, and managing loss to 
follow-up. The Population-based HIV Impact Assessment 
survey series and other household surveys have 
attempted to include direct measures of HIV incidence 
via recency assays5 and many countries are introducing 
routine recency testing for newly diagnosed individuals;6 
however, these data are not yet as widespread as data 
related to HIV prevalence and concerns remain regarding 
the validity and reliability of recency assays for accurately 
estimating HIV incidence.7
Because trends in HIV incidence and mortality are 
largely not directly observed at the national level in 
sub-Saharan Africa, estimates are developed by fitting 
mathematical models to data on trends in HIV prevalence. 
The Estimation and Projection Package (EPP),8 developed 
by UNAIDS and also used by the Global Burden of 
Disease (GBD) study,9,10 provides a well-tested structure 
for leveraging the HIV prevalence data available from 
population surveys and antenatal care sentinel surveil-
lance sites to estimate HIV incidence and mortality. 
UNAIDS, the President’s Emergency Plan for AIDS 
Relief, and others have called for incorporating local data 
and estimates into country HIV response strategies, 
given subnational heterogeneity in the HIV epidemic. 
Although subnational estimates of HIV prevalence and 
antiretroviral therapy (ART) coverage are increasingly 
common, to our knowledge, estimates of HIV incidence 
and mortality are not yet routinely available below the 
first administrative level.
Here, we present a modified version of the EPP model, 
which combines developments in spatial demography,11 
fine-scale HIV prevalence mapping,12 and HIV pandemic 
modelling9,10,13 to produce estimates of HIV incidence and 
mortality for first-level (eg, provinces) and second-level 
administrative units (eg, districts) across 44 sub-
Saharan African countries. Estimates of these indicators 
at this fine spatial scale can assist in tracking and 
accelerating progress towards meeting the Sustainable 
Development Goal of “ending the AIDS pandemic as a 
public health threat by 2030”.14
Methods
Study design
Our study follows the Guidelines for Accurate and 
Transparent Health Estimates Reporting (appendix 
pp 18, 19).15 We used a modified version of the EPP 
mathematical compartmental model, tailored specifi cally 
to estimate HIV incidence and mortality, among indi-
viduals aged 15–49 years for first-level and second-level 
administrative units in 44 countries in sub-Saharan 
Africa. EPP fits the transmission rate to the prevalence 
Research in context 
Evidence before this study
We searched PubMed with no language restrictions for 
articles published since database inception until Dec 31, 2020, 
using the following search terms: “hiv[MeSH] AND 
(“mortality” OR “incidence” OR “prevalence”) AND 
“subnational” AND (trend*)”. Previous research has shown 
that substantial local (spatial) variation exists in 
HIV incidence, and modelling studies comparing 
geographically targeted with non-geographically targeted 
prevention strategies have suggested that geographically 
targeted strategies are more efficient in preventing new 
HIV infections under the same budgetary constraints. Trends 
in HIV mortality and incidence have varied at both regional 
and country levels, resulting in differing trends in 
HIV prevalence, and this dynamic is further complicated by 
the paucity of directly observed empirical data on 
HIV incidence and mortality in sub-Saharan Africa and other 
high-burden low-income and middle-income countries. 
Renewed commitment is required to assess progress towards 
global targets at a subnational scale, to ensure no 
sub-populations are left behind, and to support 
sub-Saharan Africa in getting on track to bring HIV infection 
under control by 2030.
Added value of this study
Although many initiatives provide national estimates for 
HIV metrics (and at the administrative level in some countries), 
there are few HIV incidence and mortality estimates and 
necessary methodological innovation at more detailed 
subnational scales. This study suggests substantial variation 
exists in HIV incidence and mortality rates both between and 
within countries in sub-Saharan Africa, with highly variable rates 
of reduction in HIV incidence and mortality and the ratio of new 
infections to the number of people living with HIV from 
2000 to 2018. Although most second-level administrative units 
had declines in the number of new cases and attributable deaths, 
nearly all appeared well short of the targeted 75% reduction in 
new cases and deaths between 2010 and 2020.
Implications of all the available evidence
By improving and extending existing HIV incidence and 
mortality estimates in sub-Saharan Africa at a subnational 
scale, this study provides valuable estimates to help gauge 
progress towards ending the HIV epidemic by 2030 
(Sustainable Development Goal 3) and provides an important 
tool to improve the precision and efficiency of targeting 
interventions within countries.
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using a series of assumptions about how the different 
epidemic indicators relate to each other within a given 
population. This fitting is achieved using the Bayesian 
incremental mixture importance sampling solver, which 
aligns the HIV prevalence output of each EPP simulation 
to the HIV prevalence from our model-based geostatistical 
prevalence model. Analyses were done using the R 
(version 3.6.1) and C (version GNU99) programming 
languages. Further details of the methods, input data 
types and sources, and assumptions are provided in the 
appendix (pp 20–30).
Modelling strategy
Rather than develop a methodology de novo, we sought a 
tested modelling framework that (1) could leverage HIV 
prevalence data to estimate HIV incidence and mortality; 
(2) could use available demographic data without 
requiring calibration of many behavioural parameters 
that are rarely available at subnational resolutions; and 
(3) had a history of producing reliable and widely used 
results. EPP8 meets these needs and this system has 
been used by both UNAIDS13,16 and GBD9,10 to produce 
national and first-administrative level estimates of HIV 
incidence and mortality across sub-Saharan Africa.
EPP is a compartmental epidemiological model, 
which is designed to estimate the HIV incidence and 
mortality rates needed to produce a time trend specific 
to HIV prevalence. The model functions by varying 
model parameters to identify HIV incidence trends that 
are most consistent with observed HIV prevalence, 
given the number of patients on ART (appendix 
pp 20–30). The version of EPP that we present here is a 
modified version of that used to create the GBD 2017 
HIV estimates9 and operates on individuals aged 
15–49 years of both sexes as one intermixing population. 
Developments in EPP13 have allowed UNAIDS and 
GBD to use an age-specific and sex-specific version of 
EPP (EPP-ASM) for national models and, in some 
cases, at the first administrative level. However, use of 
that model was not feasible for our spatially granular 
implementation because of the additional compu-
tational burden of fitting this more complex model and 
because EPP-ASM benefits from age-specific and 
sex-specific HIV prevalence estimates, which are not 
yet widely available for second-level administrative 
units. We modified the GBD 2017 version of EPP to 
use the HIV prevalence time series produced using 
a model-based geostatistical framework,12 as opposed 
to direct survey and antenatal care estimates of 
HIV prevalence, which are typically used in EPP. 
Because internal migration between second-level 
administrative units is potentially important for our 
model but difficult to measure, we adopted the approach 
now being used by UNAIDS and the GBD in the 
EPP-ASM model to adjust the population at the end of 
each timepoint to the expected population in the next 
timepoint using a simple scalar. This method removes 
the need to explicitly model migration and instead 
relies on the population count estimates in each 
administrative unit. Our last major modification to EPP 
was to implement the r-hybrid model employed by 
UNAIDS in 2018 and GBD in 2019, which has been 
shown to work best for most geographical areas.13 In 
brief, r-hybrid estimates the HIV transmission rate 
differently in the early versus later phases of the 
HIV epidemic to better match observed data.
Model inputs
The model has five key inputs: (1) the boundaries (or 
shapes) used to define the second-level administrative 
units we are modelling; (2) the size of the population aged 
15–49 years over time that we used as the demographic 
bases for the hypothetical epidemics; (3) the modelled 
HIV prevalence in each of the second-level administrative 
units; (4) the number of people on ART in each second-
level administrative unit; and (5) the assumptions used 
about how likely a person living with HIV is to die from 
their infection.
To delineate the boundaries of the second-level admini-
strative units we began with the second-level admini-
strative shapefiles that are publicly available from the 
Database of Global Administrative Areas. These boun-
daries were modified to correct for known errors and to 
accommodate recent boundary changes. A full list of 
changes and the naming convention for first-level and 
second-level administrative units across the 44 countries 
in sub-Saharan Africa can be found in the appendix 
(pp 49–51).
To estimate populations in second-level administrative 
units, we used high-resolution gridded population 
estimates that were age specific and sex specific from 
WorldPop.11 To create a full time series from 1970 
to 2020, we interpolated additional years of data using 
the population growth rate at the pixel level observed in 
the WorldPop dataset, assuming exponential growth, and 
scaled the total population in each country to match GBD 
national population estimates. Finally, these gridded 
population estimates were aggregated fractionally to the 
shapefiles as described, to create second-level admini-
strative unit population estimates.
We used an updated version of the model-based 
geostatistical methodology from our previous work12 to 
produce HIV prevalence estimates for all second-level 
administrative units across sub-Saharan Africa from 
1995 to 2018. This year range was chosen because we 
were able to extract geolocated sentinel surveillance data 
for antenatal care and household survey estimates of 
HIV prevalence over this period. A full list of HIV 
prevalence data incorporated into this analysis can be 
found in the appendix (pp 52–101). In summary, 
145 surveys (80 surveys with microdata, 28 survey 
reports, and 37 surveys extracted from published 
literature) and 134 sources of antenatal care sentinel 
surveillance data, which in combination resulted in a 
For the Database of Global 
Administrative Areas see 
http://www.gadm.org
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geopositioned data set of 29 072 survey observations and 
11 710 site-years of antenatal care sentinel surveillance, 
formed the input for the HIV prevalence component.
We used several data sources to estimate the number of 
individuals on ART in each second-level adminis trative 
unit. The UNAIDS annual estimate files17 provide the 
number of adults receiving ART in each country but this 
information is not sufficiently granular to use at the 
second administrative unit level. Therefore, we did a 
systematic data-seeking exercise to extract all available 
subnational ART data in the 44 countries included in this 
analysis and successfully identified subnational-level 
ART information in 29 countries (appendix pp 201–03). 
In countries where subnational ART infor mation was 
available, we modelled these data to create a full time 
series (appendix pp 27–29). In the 15 countries where we 
were unable to locate subnational ART information, we 
assumed that the national ART coverage rate was 
consistent in all second-level adminis trative units and 
redistributed ART patients accordingly.
HIV mortality rates were calculated for individuals 
with HIV of varying disease severity separately for 
those who were and were not receiving ART.10 EPP 
divides the population with HIV into seven CD4 cell 
count categories as a proxy for disease severity and into 
two treatment categories (on or off ART). We tracked 
progression through the CD4 categories and onto 
treatment so that at every time step of the EPP model, 
we had an estimate of the size of the population for each 
disease severity and treatment category (appendix p 30). 
We then applied the estimated HIV mortality rate from 
GBD that is specific to each CD4 and treatment category 
to the population in these groups to estimate HIV 
mortality.
Effect of ART
ART is a key input to this model because the treatment 
substantially decreases viraemia and thus the probability 
that an individual with HIV will die from or pass on 
their infection;18 thus, ART fundamentally changes the 
relationship between HIV incidence, prevalence, and 
mortality. We were not able to identify and extract 
subnational ART information in all countries, and so, to 
assess the effect of using these data, in the 29 countries 
where we were able to extract subnational ART data we 
ran EPP using both the extracted subnational ART data 
and assuming the national ART coverage rate. We then 
compared the two scenarios to ascertain the effect of 
ART on our models. As expected, ART coverage in each 
second-level administrative unit had a substantial effect 
on the HIV incidence and mortality estimate in that 
location (appendix pp 31, 32). Subnational variation in 
HIV incidence and mortality, however, was still present 
in countries where we assumed the national ART 
coverage for all second-level administrative units, driven 
by variation in the level and trend of HIV prevalence. 
Figures in the appendix (pp 33–36) show the relationship 
between estimated HIV incidence, mortality, prevalence, 
and ART coverage.
Uncertainty interval estimation
To account for uncertainty in our model inputs, including 
the disease progression and mortality parameters, we ran 
100 simulations of EPP varying these parameters. Within 
each simulation, we generated 1000 draws from the 
approximated posterior distribution of HIV prevalence, 
Figure 1: HIV incidence among individuals aged 15–49 years in sub-Saharan Africa in 2018
Incidence among individuals aged 15–49 years by (A) country, (B) first-level administrative unit, and (C) second-level 
administrative unit. Lakes and areas with fewer than ten people per 1 × 1 km and classified as barren or sparsely 
vegetated are coloured light grey. Areas in dark grey were not included in the analysis. Estimates in areas that are 
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HIV incidence, and HIV mortality. To create a single, 
combined posterior distribution we sampled ten draws 
from each of the 100 simulations and then combined 
these draws. For consistency with national-level estimates 
using much of the same underlying data, we calibrated 
our results to match the estimates from the GBD 2019.10 
Further details are provided in the appendix (pp 24, 25).
To account for uncertainty in our estimates of HIV 
incidence and mortality when assessing progress towards 
achievement of the UNAIDS target of a 75% reduction 
in new HIV infections and HIV deaths, we calculated 
the posterior probability of achieving these targets as the 
percentage of draws from the estimated posterior 
distribution where these targets were achieved.
Role of the funding source
The funders of this study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
We found marked regional differences in HIV incidence 
and mortality among individuals aged 15–49 years from 
Jan 1, 2000, to Dec 31, 2018. Across the entire modelled 
region in 2018, the HIV incidence rate was 218·1 
(95% uncertainty interval [UI] 196·4–239·1) cases per 
100 000 people and the HIV mortality rate was 87·2 
(76·6–101·1) deaths per 100 000 people. At the national 
level in 2018, HIV incidence ranged from 2·8 
(2·1–3·8) cases per 100 000 people in Mauritania to 
1585·9 (1369·4–1824·8) cases per 100 000 people in 
Lesotho (figure 1A; appendix p 37), and HIV mortality 
ranged from 0·8 (0·7–0·9) deaths per 100 000 people in 
Mauritania and 676·5 (513·6–888·0) deaths per 
100 000 people in Lesotho (figure 2A; appendix p 39). The 
variation in both incidence and mortality was substantially 
greater at the subnational compared with the national 
level and the highest estimated rates were accordingly 
higher. The first-level administrative unit with the highest 
estimated HIV incidence rate in 2018 was Gaza Province 
in Mozambique, with an incidence rate of 2805·9 
(2118·0–3611·2) cases per 100 000 people (figure 1B). 
Among second-level administrative units, Guijá District 
in Gaza Province, Mozambique, had the highest 
estimated HIV incidence, with 4661·7 (2544·8–8120·3) 
cases per 100 000 people in 2018 (figure 1C). Among 
second-level administrative units, Inhassunge District in 
Zambezia Province, Mozambique, had the highest HIV 
mortality rate estimate at 1163·0 (679·0–1866·8) deaths 
per 100 000 people (figure 2C).
In addition to large-scale variation across the region, 
we also found substantial within-country variation in 
HIV incidence and mortality. In 2018, 15 countries 
(Angola, Benin, Burkina Faso, Burundi, Cameroon, 
Democratic Republic of the Congo, Ethiopia, Kenya, 
Mozambique, Nigeria, Senegal, Somalia, Tanzania, 
Uganda, and Zambia) had a greater than ten-times 
difference in HIV incidence between the second-level 
administrative units with the lowest and highest 
estimated incidence levels. Of those 15 countries, 11 also 
had a greater than ten-times difference in HIV mortality 
rates between their lowest and highest second-level 
administrative units. Kenya was a particularly extreme 
example of this variability, with incidence rate esti-
mates ranging from 14·2 (95% UI 4·1–41·3) cases per 
100 000 people in Eldas Constituency, Wajir County, 
Figure 2: HIV mortality among individuals aged 15–49 years in sub-Saharan Africa in 2018
(A) HIV mortality among individuals aged 15–49 years by country, (B) first-level administrative unit, and (C) 
second-level administrative unit. Lakes and areas with fewer than ten people per 1 × 1 km and classified as barren or 
sparsely vegetated are coloured light grey. Areas in dark grey were not included in the analysis. Estimates in areas 
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to 1767·0 (939·7–2957·9) cases per 100 000 people in 
Rarieda Constituency, Siaya County, and HIV mortality 
rate estimates ranging from 5·7 (2·4–15·2) deaths per 
100 000 people in Eldas Constituency, Wajir County, 
to 789·5 (524·9–1165·1) in Suba Constituency, Homa 
Bay County, in 2018.
In absolute terms, incident HIV cases and HIV 
deaths were highly concentrated in high-population 
locations. In 2018, we estimated 1 138 827 (95% UI 
1 025 447–1 248 270) incident HIV cases across the 
44 modelled countries. 50% of these incident HIV cases 
in 2018 were located in just 148 (3·6%) of 4087 second-
level administrative units that collectively represented 
13·7% of the total population in this region (figure 3A). 
Most of these high-burden administrative units were 
located in southern sub-Saharan Africa; in particular, 
both Lesotho and South Africa had more than 50% of 
their second-level administrative units in this category. 
Conversely, 2630 (64·4%) of 4087 second-level adminis-
trative units, representing 38·2% of the total popu-
lation, accounted for less than 10% of the total estimated 
incident HIV cases.
In 2018, we estimated that 455 244 (95% UI 
399 851–527 712) HIV deaths took place in the 
44 modelled countries. Only 224 (5·5%) of 4087 second-
level administrative units, representing 22·3% of the 
total population, accounted for 50% of the estimated 
deaths (figure 3B). 2364 (57·8%) of 4087 second-
level administrative units, representing 30·0% of the 
total popu lation, contributed less than 10% of the total 
estimated HIV deaths in 2018.
The UNAIDS fast-track goals,2 which are designed 
to set measurable targets for public health action, call 
for a 90% reduction in both incident HIV cases and 
HIV deaths by 2030, as compared with 2010 levels. An 
additional intermediate target was set to a 75% reduction 
in both indicators by 2020. Across our modelled region, 
incident HIV cases reduced by 16·9% (95% UI 6·8–25·1) 
and the HIV incidence rate reduced by 33·8% 
(25·8–40·3) between 2010 and 2018, both falling well 
short of the UNAIDS intermediate goal to reduce 
HIV incidence by 75% by 2020. We estimated that no 
country has yet achieved the goal of a 75% reduction 
in new infections on a national scale (figure 4D). Our 
estimates show wide variability among subnational areas 
in progress towards achieving this goal. We estimated 
that only six (0·9%) of 686 first-level administrative 
units (figure 4B) and 64 (1·6%) of 4087 second-level 
administrative units (figure 4C) had already achieved a 
75% reduction in incident HIV cases by 2018.
Our estimates suggest that increases in the number of 
incident HIV cases are far too common. At the national 
level, Angola (61·2% [95% UI 49·2–73·9] increase), 
Equatorial Guinea (77·3% [52·1–103·8]), Guinea (14·3% 
[0·72–32·2]), Madagascar (54·0% [32·7–80·3]), 
Mozambique (9·3% [0·7–19·5]), Sierra Leone (22·1% 
[6·4–40·2]), and Sudan (62·7% [48·8–79·6]) all had an 
increase in incident HIV cases with greater than 95% 
posterior probability (figure 4A). Increases in estimated 
incident HIV cases occurred in 130 (19·0%) of 686 first-
level administrative units that were distributed across 
18 countries (figure 4B). 771 (18·9%) of 4087 second-level 
Figure 3: Incident HIV cases and deaths among individuals aged 15–49 years in sub-Saharan Africa in 2018
(A) Number of incident HIV cases and (B) HIV deaths among individuals aged 15–49 years in 2018 by second-level administrative unit. Lakes and areas with fewer 
than ten people per 1 × 1 km and classified as barren or sparsely vegetated are coloured light grey. Areas in dark grey were not included in the analysis. Estimates in 

















www.thelancet.com/hiv   Vol 8   June 2021 e369
administrative units across 24 countries had an increase 
in the estimated number of new infections between 
2010 and 2018 (figure 4C). At the second-level 
administrative unit, the two districts with the largest 
estimated increases in HIV incidence from 2010 to 2018 
were located in Mozambique and South Africa (figure 
4D), with estimated increases in HIV incidence in 
excess of 50% over this period. Fewer locations saw an 
increase in the estimated HIV incidence rate and those 
increases were generally smaller in scale than 
corresponding changes in the number of new infections 
(appendix p 41), underscoring the effect of population 
growth on the pandemic.
We estimated reductions in HIV deaths that were 
more widespread. Across the modelled countries, HIV 
deaths fell by 38·3% (95% UI 34·6–41·5) from 2010 
to 2018. Although a substantial improvement, this 
reduction was still well short of the 75% reduction 
hoped to be achieved by 2020. Only one country, 
Burundi, achieved this benchmark at a national scale 
Figure 4: Percentage reduction in incident HIV cases in sub-Saharan Africa from 2010 to 2018
(A) Reduction in the number of incident HIV cases (%) between 2010 and 2018 among individuals aged 15–49 years by country, (B) first-level administrative unit, 
and (C) second-level administrative unit. Lakes and areas with fewer than ten people per 1 × 1 km and classified as barren or sparsely vegetated are coloured light grey. 
Areas in dark grey were not included in the analysis. Estimates in areas that are crossed are based on national, rather than subnational, estimates of 
antiretroviral therapy coverage only. A 75% reduction in HIV incidence by 2020 is a UNAIDS fast-track goal. Progress towards this target by country highlighting the 
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(figure 5A, D). Conversely, Angola, Equatorial Guinea, 
Madagascar, and Sudan had the largest increases 
in estimated HIV deaths at the national scale from 2010 
to 2018 (figure 5D). 44 (6·4%) of 686 first-level adminis-
trative units had achieved the 75% reduction in HIV 
deaths by 2018 (figure 5B) and 263 (6·4%) of 4087 
second-level administrative units showed a 75% or 
greater reduction in HIV deaths since 2010. These 
second-level administrative units were spread across 
seven countries: Burundi, Côte d’Ivoire, Democratic 
Republic of the Congo, Kenya, Nigeria, Tanzania, and 
Uganda (figure 5C).
Angola (53·0% increase [95% UI 45·1–61·8]), 
Chad (31·3% [12·6–51·4]), Equatorial Guinea (38·7% 
[19·1–59·3]), Guinea (11·9% [0·1–24·9]), Madagascar 
(39·4% [26·0–55·8]), and Sudan (32·3% [24·1–42·4]) all 
had increases in the number of estimated HIV deaths 
between 2010 and 2018 (figure 5A, D). At the first-level 
Figure 5: Percentage reduction in HIV deaths in sub-Saharan Africa from 2010 to 2018
(A) Reduction in the number of HIV deaths (%) between 2010 and 2018 among individuals aged 15–49 years by country, (B) first-level administrative unit, and (C)
second-level administrative unit. Lakes and areas with fewer than ten people per 1 × 1 km and classified as barren or sparsely vegetated are coloured light grey. Areas 
in dark grey were not included in the analysis. Estimates in areas that are crossed are based on national, rather than subnational, estimates of antiretroviral therapy 
coverage only. A 75% reduction in HIV deaths by 2020 is a UNAIDS fast-track goal. Progress towards this target by country highlighting the best and worst performing 
subnational units is shown in panel D.
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administrative unit scale, 129 (18·8%) of 686 units 
showed an increase in HIV deaths (figure 5B). Almost a 
fifth (18.6%; 762 of 4087) of second-level administrative 
units had an estimated increase in HIV deaths over 
the 2010–18 period. These units were spread across 
24 countries but Angola, Chad, Equatorial Guinea, 
Madagascar, Mauritania, and Sudan had more than 75% of 
their second-level administrative units show increases 
in HIV deaths over the period (figure 5C). Population 
growth over the period 2010–18 meant that reductions in 
the HIV mortality rate were more common and generally 
on a larger scale than reductions in the number of 
HIV deaths (appendix p 42).
We found that very few locations had even a moderate 
posterior probability of having had achieved the UNAIDS 
targeted reduction in HIV incidence (appendix pp 43, 44). 
More locations, in Burundi, Democratic Republic of 
Congo, Nigeria, Tanzania, and Uganda, had at least 
a 50% posterior probability of having achieved the 
UNAIDS targeted reduction in HIV deaths (appendix 
pp 45, 46).
Understanding the ratio of the number of new 
infections to the number of people living with HIV 
(IPR) provides critical information regarding how well 
the HIV pandemic is being brought under control. An 
IPR below 0·03 has been suggested as a benchmark 
value because the number of people living with HIV 
is expected to shrink over time below this threshold.1 
At the national level, two countries (Burundi and 
Zimbabwe) had achieved this goal in 2018 (figure 6A). 
66 first-level administrative units in 19 countries had 
estimated IPR values below 0·03 in 2018 (figure 6B); 
583 second-level administrative units in 22 countries 
also had estimated IPR values below 0·03 in 2018 
(figure 6C). To account for uncertainty in whether or 
not an administrative unit had achieved this goal as a 
result of uncertainty in our incidence and prevalence 
estimates, we calculated the posterior probability that 
the IPR in each administrative unit was below 0·03 
(appendix p 47).
Discussion
Our estimates, the first set of HIV incidence and 
mortality estimates available for all second-level 
administrative units across sub-Saharan Africa, suggest 
highly variable levels of HIV incidence and mortality as 
well as variable rates of reduction. Nonetheless, most 
second-level administrative units in the region appear 
to be falling well short of the targeted 75% reduction in 
new cases and deaths by 2020. Previous spatial analyses 
of the HIV pandemic across sub-Saharan Africa have 
mainly focused on prevalence because of the lack of 
spatially explicit HIV incidence and mortality data. HIV 
prevalence estimates and the corresponding estimates 
of the number of people living with HIV are useful for 
measuring the need for treatment and related services; 
nonetheless, most benchmarks and targets are related 
to HIV incidence and mortality because these metrics 
are more sensitive, timely indicators of the progression 
of the HIV epidemic, compared with prevalence 
estimates. The estimates we present here, in con-
junction with the HIV prevalence estimates12 on which 
they are based, provide a granular picture of how the 
HIV pandemic is progressing in communities across 
sub-Saharan Africa. These estimates can be used for 
programmatic targeting and subnational goal setting in 
Figure 6: HIV incidence to prevalence ratio in sub-Saharan Africa in 2018
Number of new infections among individuals aged 15–49 years divided by the number of individuals living with 
HIV aged 15–49 years by (A) country, (B) first-level administrative unit, and (C) second-level administrative unit. 
Lakes and areas with fewer than ten people per 1 × 1 km and classified as barren or sparsely vegetated are coloured 
light grey. Areas in dark grey were not included in the analysis. Estimates in areas that are crossed are based on 
national, rather than subnational, estimates of antiretroviral therapy coverage only. Achieving a sustained 
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the fight against HIV. Modelling studies have shown 
improved programme efficiency when prevention 
services are geographically targeted using an under-
standing of local epidemiology.3,4 Moreover, studies in 
South Africa have identified geographical hotspots 
as crucial to the spread of HIV more broadly.19 Our 
estimates provide a mechanism to identify second-level 
administrative units where HIV incidence rates are 
predicted to be particularly high and might warrant 
further investigation as potential hotspots of HIV 
infection as well as areas requiring additional invest-
ment to improve both coverage and quality of services. 
Although the rapid scale-up of ART towards the 
UNAIDS 90-90-90 goals has already contributed to 
substantial reductions in HIV incidence and mortality 
in sub-Saharan Africa, there has been considerable 
debate as to whether universal test and treat can end 
the epidemic in the region. A modelling study using 
Eswatini as a case study suggests that even when 
assuming the most ideal scenarios, meeting ART 
coverage targets alone will be insufficient to bring 
infections below epidemic control levels in the most 
intense HIV epidemic settings.20 This finding suggests 
that highly endemic countries could achieve the 
90-90-90 target thresholds but still have incidence 
rates above the epidemic control threshold (incidence 
<1 infection per 1000 person-years) and further high-
lights the need for incidence and mortality estimates at 
subnational scales to assess progress in addition to the 
universal test and treat targets. Lastly, these estimates 
make it possible to identify areas where HIV mortality 
rates are still predicted to be high, which similarly 
warrant further investigation to identify and rectify 
the root causes of poor outcomes among people living 
with HIV.
Despite substantial progress in reducing both HIV 
incidence and mortality over the past decade—faster in 
sub-Saharan Africa than in many other regions21—neither 
the number of incident HIV cases nor the number of 
HIV deaths has declined sufficiently to achieve the 
UNAIDS fast-track goals for 2020,2 and the world is not 
on track to achieve the Sustainable Development Goal of 
ending the HIV and AIDS epidemic by 2030.14 Further 
progress might even be more challenging, given the 
stagnation of development assistance for health focused 
on HIV22 and the widespread disruptions of intervention 
efforts due to the myriad detrimental influences of 
COVID-19 on health systems.23 Renewed efforts and new 
tools are needed to ultimately bring HIV infection under 
control in sub-Saharan Africa and globally. The methods 
and resulting estimates described here provide one such 
tool to contribute to the monitoring and assessment of 
these efforts.
A comparison of our country-level estimates with 
those from UNAIDS, although largely similar, suggests 
a few notable differences, for example in Lesotho and 
Sierra Leone. Although the methodological approach 
and data inputs used by UNAIDS, the present study, 
and GBD (to which our estimates are calibrated) are 
broadly similar, several differences in the approach 
exist nonetheless. Differences include, for example, 
differences in the disease progression and mortality 
parameters used in EPP and in the data inputs used, 
which can lead to meaningful differences in the 
resulting estimates of HIV burden. More generally, in 
some cases the underlying data are ambiguous and 
different analyses of these data might reasonably reach 
different con clusions, although generally with sub-
stantial uncertainty. In these cases, the differences 
between estimates generated using different approaches 
and by different research groups present an opportunity 
to compare estimates and to further interrogate the 
underlying data. Despite these differences, comparison 
with available and recent estimates for Lesotho24 and 
Sierra Leone,25 for example, suggest that our estimates 
have face validity.
Our methods for estimating subnational HIV incidence 
and mortality are subject to several limitations, as are 
most studies of this type. Estimates derived from EPP 
are only as reliable as the inputs provided. We included 
no direct measures of HIV incidence or mortality in our 
modelling process, primarily because of the rarity of 
such data at local levels. This paucity of directly observed, 
gold-standard data makes validating our estimates 
difficult and, as such, these estimates should be used 
with caution and in conjunction with local HIV 
programme information. Furthermore, large-scale 
household surveys are generally powered to produce 
design-based estimates at the scale of the national or 
first-administrative level only.
A second limitation relates to migration. Human 
movement was an important driver of the early HIV 
pandemic26 and still remains one of the key features 
driving HIV incidence.19,27 Subnational migration data 
are scarce and limited in terms of geographical represen-
tative ness and generally do not capture differential rates 
of migration among HIV-positive and HIV-negative 
individuals, and so our model assumes that any in-
migrant population has the same HIV prevalence as 
that of the population already residing in that area. 
Furthermore, data on circular migration for labour 
are also scarce and limited in terms of geographical 
coverage and difficult to model dynamically in space-
time. Our modelled HIV incidence should be inter-
preted as the number of new infections in the resident 
population of a second-level administrative unit needed 
to maintain the measured HIV prevalence in that 
population, thus, we make no claims about where HIV 
transmission took place among mobile populations. 
Future modelling efforts that can explicitly model long-
term and circular human movement will be a substantial 
improvement in this regard.
A third limitation of our model is ART data with poor 
spatial granularity. In 15 countries, we were only able to 
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identify ART data at the national level and this lack of 
subnational ART information has meaningful effects 
on our modelled estimates. Furthermore, even in cases 
where ART data were available for each second-level 
administrative unit, these data were most often 
tabulated by where ART was received, rather than by 
the patient’s residence. Although evidence exists that 
people living with HIV in some cases cross internal 
borders when seeking treatment,28 we were not able to 
account for this in our analysis. ART coverage also has 
limitations as a proxy effect indicator because variations 
in adherence and retention imply ART coverage might 
only be a loose measure of actual clinical efficacy.29 
Further, ART is not the only intervention expected 
to affect HIV incidence and mortality and future 
work should consider incorporating other important 
inter ventions (eg, pre-exposure prophylaxis30) as data 
allow. Moreover, incorporation of additional steps in 
the treatment cascade, particularly diagnosis,31 into the 
modelling framework could strengthen the estimates 
and provide additional useful indicators.
A fourth limitation relates to the age groups modelled. 
Specifically, EPP treats the entire population aged 
15–49 years as a single group, whereas EPP-ASM 
stratifies the underlying population by age and sex. We 
chose to use EPP for this analysis to limit computational 
burden and because we expected the benefits of EPP-
ASM to be most apparent when fit to prevalence data 
that are age specific and sex specific, which are not yet 
widely available at a fine subnational scale. However, we 
have ongoing work aimed at estimating age-specific and 
sex-specific prevalence on a local scale, which will help 
to fill this gap, and using these estimates and EPP-ASM 
to produce age-stratified and sex-stratified estimates of 
HIV incidence and mortality on a subnational scale is 
an important area for future research. Additionally, our 
study was limited to individuals aged 15–49 years and 
did not consider trends in paediatric HIV, although 
local variation in paediatric HIV incidence and mortality 
is likely to exist. Future work should aim to include 
relevant paediatric data sources to account for this 
potential heterogeneity.
Finally, many of the inputs used in this analysis—
including HIV prevalence, ART coverage, population 
size and age and sex structure, and disease and 
mortality progression parameters—are themselves 
estimates and are subject to error, which will likely be 
propagated into our estimates of HIV incidence and 
mortality. Where possible (ie, for HIV prevalence 
and the disease progression and mortality parameters) 
we have propagated the uncertainty inherent in these 
underlying inputs into the reported UIs for HIV inci-
dence and mortality. However, we could not quantify 
the uncertainty in ART coverage or population size 
or structure and could not reflect this uncertainty in 
our reported UIs. Consequently, the UIs are likely 
to underestimate true uncertainty to some degree, 
although the extent of this underestimation is difficult 
to assess.
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